JK07

· Salubris Biotherapeutics Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for JK07, covering 2025-07-09 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension [Phase 2]

See pricing